Mouse wearable micro injection equipment for slowly releasing salidroside

Abstract

The invention discloses mouse wearing type micro injection equipment for salidroside slow release, and relates to the technical field of medical micro equipment. Comprising a fixing frame, a slow injection device arranged at the upper end of the fixing frame and a fluid director connected with the slow injection device, the slow injection device comprises an injector body internally provided with a liquid storage area and a reaction area, an injection plug is arranged between the liquid storage area and the reaction area, and meanwhile the side edge of the injection plug is attached to the inner wall of the injector body. And the fluid director is communicated with the liquid storage area. Through three different reaction mechanisms, namely gas driving of the medicine bin, physical expansion of the expansion bag and composite expansion of the expansion bin, accurate regulation and control of the medicine release rate can be achieved, meanwhile, due to the design of the ear hanging openings in the fixing frame, ear pressure can be dispersed, and meanwhile by combining the design of the light-weight structure, the application range is wide. And the fluctuation range of corticosterone level of mice can be reduced.

Description

Technical Field

[0001] The present invention relates to the technical field of medical miniaturization equipment, in particular to a mouse-wearable micro-injection device for sustained-release of salidroside. Background Art

[0002] Salidroside (C14H20O7) has low oral bioavailability (only 15%–20% in rat models) and a short half-life (approximately 2.5 hours), requiring frequent dosing to maintain effective blood concentrations (Zhang et al., Phytomedicine, 2018). Traditional methods, such as daily intraperitoneal injection, can easily lead to elevated stress-induced corticosterone levels in mice, compromising the reliability of neuroprotection experimental results.

[0003] A Chinese utility model patent, publication number CN215961537U, discloses a drug liquid infusion mechanism based on a separate drug reservoir and syringe, comprising a drug reservoir, a reversing valve, a valve control device, a syringe, a propulsion mechanism, and an injection needle. The reversing valve comprises a valve slider and a valve housing, with the valve slider mounted within the valve housing. The valve slider is slotted, and the valve housing is provided with one or more openings. The opening on one side of the valve housing connects to the drug reservoir, the opening in the middle of the valve housing connects to the syringe, and the opening on the other side of the valve housing connects to the injection needle. The valve control device comprises a valve slider fixture and an axial electromagnet. This utility model allows for full miniaturization and compactness, with a thinner tube diameter and improved precision proportional to the area ratio. This reduces the pump body size while maintaining sufficient drug volume, making it easier for users to wear. Flexible piping connects the drug reservoir, reversing valve, and syringe, allowing for greater layout flexibility and reducing user costs.

[0004] While the above approach can be miniaturized and injected into mice, salidroside exhibits poor stability under physiological conditions (pH 7.4, 37°C). Its aqueous solution degrades by as much as 30-40% within 24 hours, and its half-life under natural light is only 6-8 hours. Furthermore, repeated injections of salidroside activate the hypothalamic-pituitary-adrenal axis in mice, leading to significant fluctuations in plasma corticosterone levels. Surgical implantation can lead to local infection or tissue adhesions in 15-20% of mice. Furthermore, the pre-implantation dose is fixed, making it impossible to adjust the dose based on weight changes or drug response during the experiment. This means that reducing the frequency of dosing will require a longer release period, which can compromise drug stability. Improving drug stability, on the other hand, requires complex packaging, which increases device size and implant trauma. Summary of the Invention

[0005] The object of the present invention is to provide a mouse-wearable microinjection device for sustained-release of salidroside, so as to solve the problems raised in the above-mentioned background technology.

[0006] To achieve the above objectives, the present invention provides the following technical solutions: a wearable microinjection device for mice for sustained release of salidroside, comprising a fixing frame, a slow injection device disposed at the upper end of the fixing frame, and a flow guide connected to the slow injection device, wherein the slow injection device comprises a syringe body having a liquid storage area and a reaction area disposed therein, an injection plug is disposed between the liquid storage area and the reaction area, and the side of the injection plug is in contact with the inner wall of the syringe body, and the flow guide is in communication with the liquid storage area;

[0007] A liquid injection port connected to the reaction area and a drug injection port connected to the liquid storage area are respectively provided on both sides of the upper end of the syringe body, and the interiors of the liquid injection port and the drug injection port are filled with rubber. At the same time, one end of the syringe body is connected to the deflector and the other end is provided with a sealing cover. An active reaction component is provided inside the reaction area, and the sealing cover is provided on the side of the active reaction component. At the same time, the injection plug moves due to the changes of the active reaction component and injects the medicine inside the liquid storage area to the outside.

[0008] Furthermore, the fixing frame includes a mouthpiece, a head fixing piece and a plurality of expansion pieces connected in sequence, the strap piece located at the end of the mouthpiece and the head adapter openings located on both sides of the head fixing piece are fixedly connected by a head fixing strap, and the fixing ears located on both sides of the syringe body and the expansion pieces are fixedly connected by an auxiliary fixing strap;

[0009] Mouth rings are provided on both sides of the muzzle, the ends of the deflector pass through the mouth rings, and the ear hanging openings located on the sides of the head adapter opening fit the ears of the mouse.

[0010] Furthermore, the movable reaction component includes but is not limited to a deformable medicine chamber, an expansion bag and an expansion chamber, and the injection plug moves due to changes in the medicine chamber, the expansion bag and the expansion chamber, and at the same time, the volume of the reaction zone of the medicine chamber / expansion bag set inside is smaller than the volume of the reaction zone of the expansion chamber set inside.

[0011] Furthermore, pills are arranged inside the medicine bin opened in the middle of the sealing cover, and the pills are isolated from the reaction zone by aluminum foil, and the pills and the injection plug are arranged opposite to each other. At the same time, the pills fall into the interior of the reaction zone by pressing the medicine bin and squeezing the aluminum foil.

[0012] Furthermore, the pill includes a pill body, a wax sealing layer is provided on the outer surface of the pill body, and a notch is provided on the wax sealing layer, and the pill body is in contact with the interior of the reaction zone through the notch.

[0013] Furthermore, the expansion bag provided on the side of the injection plug facing the reaction zone includes an expansion cavity, multiple expansion drug layers and a plastic sealing tape, wherein the expansion cavity and the multiple expansion drug layers are both provided inside the plastic sealing tape, and the expansion cavity and the expansion drug layers, as well as adjacent expansion drug layers, are spaced apart by cotton sheets;

[0014] A plurality of through holes are provided on one end of the plastic sealing tape close to the expansion medicine layer, and the expansion medicine layer is connected with the interior of the reaction zone through the through holes.

[0015] Furthermore, the injection plug includes two pistons connected by a connecting rod, and an arc groove is provided on the outward side of the piston facing the liquid storage area. At the same time, the middle of the arc groove is in contact with the end of the guide, and the side of the piston facing the reaction area is in close contact with and perpendicular to the inner wall of the syringe body.

[0016] Furthermore, the interior of the expansion chamber arranged on one side of the injection plug is filled with solid expansion material and a guide strip, the expansion chamber and the reaction zone are separated by a partition, and the end of the guide strip passes through the partition and is connected to the interior of the reaction zone.

[0017] Furthermore, the guide strips arranged inside the expansion chamber are provided with redundancy, and the ends of the guide strips are connected to the sides of the injection plug in a wave-like manner.

[0018] Furthermore, the injection plug includes two pistons connected by a connecting rod, and the side surfaces of the pistons are tightly attached to and perpendicular to the inner wall of the syringe body.

[0019] Compared with the prior art, the present invention has the following beneficial effects:

[0020] First, the present invention can achieve precise control of drug release rate through three different reaction mechanisms: gas-driven drug release, physical expansion of the expansion bag, and combined expansion of the expansion chamber. At the same time, the ear-hanging design in the fixed frame can not only disperse ear pressure, but also reduce the fluctuation amplitude of corticosterone levels in mice in combination with the lightweight structure design.

[0021] Secondly, the present invention provides a spiral notch on the pill, so that as the reaction continues, the reaction area can expand over time, thereby maintaining a constant release rate;

[0022] Third: The present invention adopts a modular design of the muzzle and the head fixing plate, combined with an adjustable expansion plate and an auxiliary fixing strap, so that it can adapt to mice of different sizes. At the same time, the deflector is positioned through the mouth ring, which not only reduces the total weight of the equipment but also avoids causing additional burden on experimental animals. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 Schematic diagram of the structure of the mouse wearable microinjection device of the present invention;

[0024] Figure 2 Schematic diagram of the structure of the fixing frame in the present invention;

[0025] Figure 3 This is a schematic diagram of the structure of the slow injection device with a medicine chamber / expansion bag inside in the present invention;

[0026] Figure 4 This is a schematic structural diagram of a slow injection device with an expansion chamber inside according to the present invention;

[0027] Figure 5 It is a cross-sectional view of the slow injection device with an expansion bag inside according to the present invention;

[0028] Figure 6 It is a cross-sectional view of the slow injection device with a medicine chamber inside according to the present invention;

[0029] Figure 7 For the present invention Figure 6 Enlarged view of part A;

[0030] Figure 8 For the present invention Figure 4 Cross-sectional view of the structure;

[0031] Figure 9 A schematic structural diagram of the injection plug of the present invention;

[0032] Figure 10 Schematic diagram of another structure of the injection plug of the present invention;

[0033] Figure 11 Schematic diagram of the structure of the Chinese medicine pill of the present invention;

[0034] Figure 12 It is a structural schematic diagram of the expansion bag in the present invention.

[0035] The corresponding numbers and names of the components in the figure are:

[0036] 1. Fixing frame; 101. Mouthpiece; 102. Mouth ring; 103. Threading piece; 104. Head fixing strap; 105. Head fixing piece; 106. Head adapter; 107. Ear hanging mouth; 108. Extension piece; 109. Auxiliary fixing strap; 2. Slow injection device; 201. Syringe body; 202. Sealing cap; 203. Injection plug; 204. Liquid injection port; 205. Drug injection port; 20 6. Fixing ear; 207. Medicine chamber; 208. Medicine pill; 209. Aluminum foil; 210. Expansion bag; 211. Spacer; 212. Guide strip; 213. Expansion chamber; 214. Medicine body; 215. Wax seal layer; 216. Connecting rod; 217. Arc groove; 218. Plastic sealing tape; 219. Expansion cavity; 220. Cotton sheet; 221. Expansion medicine layer; 222. Through hole; 3. Deflector. DETAILED DESCRIPTION

[0037] The following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.

[0038] Example 1

[0039] refer to Figures 1-4 This embodiment provides a wearable microinjection device for sustained release of salidroside in mice. The wearable microinjection device comprises a fixing frame 1, a slow injector 2, and a flow guide 3. The fixing frame 1 is fixedly connected to the mouse's head via a head fixing strap 104. The slow injector 2 is disposed at the upper end of the fixing frame 1, and an auxiliary fixing strap 109 secures the fixing frame 1, slow injector 2, and the mouse's back.

[0040] In the present embodiment, the slow injection device 2 includes a syringe body 201, wherein the interior of the syringe body 201 is provided with a liquid storage area and a reaction area. Specifically, a liquid injection port 204 connected to the reaction area and a drug injection port 205 connected to the liquid storage area are respectively provided on both sides of the upper end of the syringe body 201. That is to say, a salidroside-glucose mixed solution can be injected into the liquid storage area through the drug injection port 205, and a reaction liquid can be injected into the reaction area through the liquid injection port 204. It is worth noting that the interiors of the liquid injection port 204 and the drug injection port 205 in the present embodiment are both filled with rubber. That is to say, during use, the corresponding liquid can be injected into the liquid storage area and the reaction area after the needle of the syringe penetrates the rubber. After the injection is completed and the needle of the syringe is pulled out, the elastic extrusion of the rubber itself can ensure the airtightness of the liquid storage area and the reaction area.

[0041] Furthermore, an injection plug 203 is positioned between the liquid storage area and the reaction area, with the side of the injection plug 203 abutting against the inner wall of the syringe body 201. One end of the syringe body 201 is connected to the flow guide 3, while the other end is provided with a sealing cap 202. Specifically, the end of the flow guide 3 is connected to the liquid storage area, and the flow guide 3 and the interior of the liquid storage area are in communication. The other end of the flow guide 3 extends into the mouse's mouth.

[0042] Furthermore, a movable reaction component is provided inside the reaction area, and a sealing cover 202 is provided on the side of the movable reaction component, and the injection plug 203 moves due to the change of the movable reaction component, and the medicine inside the liquid storage area is injected externally. In other words, the reaction liquid injected into the reaction area causes the movable reaction component to change, thereby driving the injection plug 203 to move toward the liquid storage area, so that under the movement of the injection plug 203, the salidroside-glucose mixture injected into the liquid storage area will flow from the inside of the liquid storage area into the flow guide 3, and under the action of the flow guide 3, enter the mouse body through the mouse mouth. Therefore, by changing the movable reaction component, micro-flow regulation of the salidroside-glucose mixture can be achieved.

[0043] Example 2

[0044] This embodiment provides a wearable microinjection device for mice for sustained release of salidroside. Its specific implementation structure is the same as that of Example 1, except that the fixing frame 1 includes a mouthpiece 101, a head fixing piece 105, and a plurality of expansion pieces 108 connected in sequence, and the mouse and the sustained injection device 2 are connected via the mouthpiece 101, the head fixing piece 105, and the plurality of expansion pieces 108. The present invention will be described below with reference to the specific implementation methods of this embodiment.

[0045] refer to Figure 2 In this embodiment, a strap piece 103 is provided at the end of the muzzle 101, and a mouth ring 102 is provided on both sides of the muzzle 101. In this embodiment, a head adapter 106 is provided on both sides of the head fixing plate 105, and an ear hook 107 is provided on the side of the head adapter 106, and the ear hook 107 is fitted with the mouse's ear.

[0046] Specifically, in this embodiment, after the muzzle 101 is passed through the mouse's mouth, the strap piece 103 is placed at the lower end of the mouse's mouth. At the same time, the head fixing piece 105 is stretched behind the mouse's ears, and the ear hooks 107 are fitted to the base of the mouse's ears. The two ends of the head fixing strap 104 are then passed through the perforations at both ends of the strap piece 103. The head fixing strap 104 is then passed through the mouse's head and then through the head adapter openings 106 on both sides of the head fixing piece 105. At this point, the two ends of the head fixing strap 104 passing through the head adapter openings 106 are fixed, and the end of the fixing frame 1 is fixed to the mouse's head.

[0047] Furthermore, in this embodiment, a plurality of expansion pieces 108 are provided, and the number of expansion pieces 108 can be adjusted according to the actual size of the mouse. Therefore, in this embodiment, the specific number of expansion pieces 108 is not specifically limited, and only six expansion pieces 108 are illustrated. In addition, in this embodiment, fixing ears 206 are provided on both sides of the syringe body 201.

[0048] Specifically, after passing the auxiliary fixing belt 109 through the abdomen of the mouse, the two ends of the auxiliary fixing belt 109 are passed through the perforations on both sides of any expansion piece 108, and then the two ends of the auxiliary fixing belt 109 are passed through the fixing ears 206 on both sides of the syringe body 201. After that, the two ends of the auxiliary fixing belt 109 are fixed, and the syringe body 201 can be fixed on the back of the mouse.

[0049] That is, after securing the syringe body 201 to the mouse, one end of the flow guide 3 is connected to the liquid outlet of the liquid reservoir of the syringe body 201. Meanwhile, the other end of the flow guide 3 is passed through the mouth ring 102 and then inserted into the mouse's mouth. This allows the salidroside-glucose mixture in the liquid reservoir to enter the mouse's body through the mouse's mouth.

[0050] Example 3

[0051] This embodiment provides a mouse-wearable microinjection device for sustained-release salidroside. Its specific implementation structure is the same as that of Embodiments 1 and 2, except that the active reaction component includes, but is not limited to, a deformable drug chamber 207, an expansion bag 210, and an expansion chamber 213. The injection plug 203 can move due to changes in the drug chamber 207, the expansion bag 210, and the expansion chamber 213, thereby delivering the salidroside-glucose mixture in the liquid storage area into the mouse through the flow guide 3. The present invention will be described below with reference to the specific implementation methods of this embodiment.

[0052] refer to Figure 6 and Figure 7 In this embodiment, the deformable drug reservoir 207 is used as an example for detailed description. In this embodiment, the drug reservoir 207 is located in the middle of the sealing cover 202 and is a soft device, meaning it can be pressed. Furthermore, pills 208 are located within the drug reservoir 207. These pills 208 are separated from the reaction zone by aluminum foil 209 and are positioned opposite the injection plug 203. Specifically, pressing the drug reservoir 207 causes the pills 208 to break through the aluminum foil 209, causing them to fall into the reaction zone.

[0053] refer to Figure 11In this embodiment, the pill 208 includes a body 214, wherein the outer surface of the body 214 is provided with a wax seal 215, and the wax seal 215 is provided with a notch. That is, after the reaction liquid is injected into the reaction zone through the liquid injection port 204, the pill 208 that falls into the reaction zone will react with the reaction liquid through the notch, causing the body 214 to react with the reaction liquid. This reaction causes the injection plug 203 to move toward the liquid storage area. As a result, the movement of the injection plug 203 causes the salidroside-glucose mixture injected into the liquid storage area to flow from the liquid storage area into the flow guide 3.

[0054] Further, refer to Figure 10 The injection plug 203 in this embodiment includes a connecting rod 216 and two pistons. The two pistons are connected by the connecting rod 216, and an arcuate groove 217 is provided on the outward side of the piston facing the liquid storage area. At the same time, the middle part of the arcuate groove 217 is in contact with the end of the flow guide 3, and the side of the piston facing the reaction area is in close contact with and perpendicular to the inner wall of the syringe body 201. In other words, when the injection plug 203 is moved by the reaction between the drug body 214 and the reaction liquid, the injection plug 203 is not prone to tilting during the movement due to the linkage effect of the two pistons. At the same time, the provision of the arcuate groove 217 can enable the salidroside-glucose mixture in the liquid storage area to be better transmitted outward during the injection process, thereby reducing the residual amount in the liquid storage area.

[0055] In this embodiment, when pills 208 are sodium bicarbonate pills, dilute acetic acid solution can be injected into the reaction zone. Since the wax seal 215 is provided with a spiral notch, pressing the medicine chamber 207 causes the sodium bicarbonate pills to break through the aluminum foil 209 and fall into the dilute acetic acid solution. Simultaneously, due to the provision of the spiral notch, the sodium bicarbonate pills and the dilute acetic acid solution will initially react through the notch. As the reaction proceeds, the wax seal 215 attached to the outside of the sodium bicarbonate pills will continue to diffuse, and the notch will continue to expand. Thus, although the sodium bicarbonate pills decrease in dosage as the reaction proceeds, the reaction area between the two continues to expand, thereby ensuring the stability of the reaction rate. In other words, the CO2 gas generated by the reaction between the sodium bicarbonate pills and the dilute acetic acid solution can increase the pressure within the reaction zone, thereby causing the injection plug 203 to move toward the liquid storage area under the action of the pressure differential.

[0056] Specifically, after the needle of the syringe penetrates the rubber in the injection port 205, the salidroside-glucose mixture can be injected into the interior of the liquid storage area, and 5% redundant space must be retained inside the liquid storage area. At the same time, after pulling out the rubber in the injection port 204, the dilute acetic acid solution is injected into the reaction area through the syringe until the injection capacity reaches 80% of the reaction area volume. The entire slow injection device 2 is tilted to allow the gas in the reaction area to be discharged from the injection port 204. Then, the dilute acetic acid solution is injected into the remaining space in the reaction area. Finally, the rubber at the injection port 204 can be filled to keep the reaction area sealed. After that, the medicine chamber 207 is pressed to allow the sodium bicarbonate pills to react with the dilute acetic acid solution.

[0057] Furthermore, when pills 208 are calcium carbonate pills, 0.5M dilute hydrochloric acid can be injected into the reaction zone. Similarly, the reaction between calcium carbonate pills and 0.5M dilute hydrochloric acid is similar to the reaction between sodium bicarbonate pills and dilute acetic acid solution. The CO2 gas generated between the two increases the pressure inside the reaction zone, thereby causing the injection plug 203 to move toward the liquid storage area due to the pressure difference.

[0058] Example 4

[0059] This embodiment provides a wearable microinjection device for mice for sustained release of salidroside, and its specific implementation structure is the same as that of Embodiments 1 and 2, except that the active reaction component in this embodiment is configured as an expansion bag 210. The present invention will be described below with reference to the specific implementation of this embodiment.

[0060] refer to Figure 5 and Figure 12 The expansion bag 210 is arranged on the side of the injection plug 203 facing the reaction zone. Specifically, the expansion bag 210 includes an expansion cavity 219, multiple expansion drug layers 221 and a plastic sealing tape 218. The expansion cavity 219 and the multiple expansion drug layers 221 are all arranged inside the plastic sealing tape 218, and the expansion cavity 219 and the expansion drug layers 221, as well as the two adjacent expansion drug layers 221, are spaced apart by cotton sheets 220. It is worth noting that the number of expansion drug layers 221 in this embodiment can be set according to the actual size of the reaction zone. In this embodiment, three expansion drug layers 221 are provided.

[0061] Furthermore, a plurality of through holes 222 are formed at one end of the plastic sealing tape 218 near the expansion drug layer 221. The through holes 222 are evenly distributed at the end of the plastic sealing tape 218 and are all connected to the interior of the reaction zone. In other words, the expansion drug layer 221 can be connected to the interior of the reaction zone through the through holes 222.

[0062] Further, refer to Figure 10The injection plug 203 in this embodiment includes a connecting rod 216 and two pistons. The two pistons are connected by the connecting rod 216, and an arcuate groove 217 is provided on the outward side of the piston facing the liquid storage area. At the same time, the middle part of the arcuate groove 217 is in contact with the end of the flow guide 3, and the side of the piston facing the reaction area is in close contact with and perpendicular to the inner wall of the syringe body 201. In other words, when the injection plug 203 is moved by the reaction between the drug body 214 and the reaction liquid, the injection plug 203 is not prone to tilting during the movement due to the linkage effect of the two pistons. At the same time, the provision of the arcuate groove 217 can enable the salidroside-glucose mixture in the liquid storage area to be better transmitted outward during the injection process, thereby reducing the residual amount in the liquid storage area.

[0063] Specifically, after the reaction liquid is injected into the reaction zone through the liquid injection port 204, the reaction liquid will enter the interior of the expansion drug layer 221 through the multiple through holes 222, causing the expansion drug layer 221 to expand. At the same time, when the first expansion drug layer 221 expands to its limit, the reaction liquid will pass through the cotton sheet 220 and enter the second expansion drug layer 221, causing the second expansion drug layer 221 to expand, until all three expansion drug layers 221 expand to their limits. It is worth noting that due to the slow expansion rate here, the injection plug 203 will slowly move toward the liquid storage area during the expansion process.

[0064] In this embodiment, the interior of the swelling drug layer 221 is filled with sodium polyacrylate particles, and physiological saline can be injected into the reaction zone. Specifically, after absorbing water through the through-holes 222, the sodium polyacrylate particles expand by 9-10 times their volume, thereby sequentially expanding each layer of cotton sheet 220. In other words, the expansion force generated by the sodium polyacrylate particles after absorbing water can be transmitted through the expansion cavity 219 to the side of the arc-shaped groove 217, thereby causing the injection plug 203 to move toward the liquid storage area.

[0065] Specifically, after the syringe needle penetrates the rubber inside injection port 205, the salidroside-glucose mixture is injected into the liquid storage area, leaving 5% of redundant space inside the liquid storage area. Simultaneously, after removing the rubber inside injection port 204, physiological saline is injected into the reaction area via a syringe. During the injection process, the saline is injected in multiple intervals to allow the gas in the reaction area to be discharged in a timely manner. Finally, the rubber at injection port 204 is filled.

[0066] Furthermore, the interior of the expansion drug layer 221 can also be filled with polyacrylamide copolymer, potassium polyacrylate and sodium polyacrylate, or different substances can be filled in different expansion drug layers 221 in sequence to form an expansion gradient, thereby allowing the injection plug 203 to move toward the liquid storage area.

[0067] Specifically, in this embodiment, the three swelling drug layers 221 are filled with polyacrylamide copolymer, potassium polyacrylate, and sodium polyacrylate, respectively. Therefore, when injecting the reaction liquid into the reaction zone, after pulling out the rubber in the injection port 204, a 5% NaCl solution is first injected into the reaction zone to wet the first swelling drug layer 221. After waiting for 10 minutes to exhaust, 0.9% physiological saline is then injected into the reaction zone to wet the second swelling drug layer 221. After exhausting again, distilled water is injected into the reaction zone to wet all swelling drug layers 221 and expand them. It is worth noting that after each injection of the reaction liquid, the outer wall of the syringe body 201 can be gently tapped to promote the rise of bubbles in the reaction zone, thereby accelerating the exhaust rate of the reaction zone.

[0068] Example 5

[0069] This embodiment provides a mouse-wearable microinjection device for sustained release of salidroside, and its specific implementation structure is the same as that of Embodiments 1 and 2, except that the active reaction component in this embodiment is configured as an expansion chamber 213. The present invention will be described below with reference to the specific implementation of this embodiment.

[0070] refer to Figure 8 , the expansion chamber 213 is arranged on one side of the injection plug 203, wherein the interior of the expansion chamber 213 is filled with solid expansion material and a guide strip 212, and the expansion chamber 213 and the reaction zone are spaced apart by a spacer 211, and the end of the guide strip 212 passes through the spacer 211 and is connected to the interior of the reaction zone. It is worth noting that the guide strip 212 arranged inside the expansion chamber 213 is redundant, and the end of the guide strip 212 is connected to the side of the injection plug 203 in a wavy manner. That is to say, after the reaction liquid is injected into the interior of the reaction zone through the injection port 204, the reaction liquid will be introduced into the interior of the expansion chamber 213 through the guide strip 212 in the reaction zone, and react with the solid expansion material inside the expansion chamber 213, causing the solid expansion material to expand, so that under the expansion action of the solid expansion material, the injection plug 203 will move toward the liquid storage area, and then the salidroside-glucose mixture injected into the liquid storage area can be flowed from the interior of the liquid storage area into the guide 3.

[0071] refer to Figure 9 In this embodiment, the injection plug 203 includes a connecting rod 216 and two pistons. The two pistons are connected by the connecting rod 216, and the side surfaces of the pistons are in close contact with and perpendicular to the inner wall of the syringe body 201. In other words, when the reaction between the solid expansion material and the reaction liquid drives the injection plug 203 to move, the linkage between the two pistons prevents the injection plug 203 from tilting during movement.

[0072] In the present embodiment, the solid expansion material includes but is not limited to a composite material of acrylic acid-acrylamide copolymer particles, solid sodium bicarbonate and sodium polyacrylate. Specifically, when the solid expansion material is acrylic acid-acrylamide copolymer particles, physiological saline can be injected into the reaction zone. That is to say, after the acrylic acid-acrylamide copolymer particles are infiltrated by the capillary action of the guide strip 212, the acrylic acid-acrylamide copolymer particles will expand and, during the expansion process, push the injection plug 203 to move toward the liquid storage area. It is worth noting that the volume of the expansion bin 213 here needs to be 1.2 times that of the liquid storage area to ensure that it can be completely emptied. In other words, the volume of the reaction zone in which the medicine bin 207 / expansion bag 210 is arranged is smaller than the volume of the reaction zone in which the expansion bin 213 is arranged.

[0073] Furthermore, the interior of the expansion chamber 213 can be filled with sodium bicarbonate solid and sodium polyacrylate in layers, and the acidic reaction liquid can be injected into the reaction zone. In other words, the capillary action of the guide strips 212 allows the acidic reaction liquid and the sodium bicarbonate solid to initially react, generating an initial thrust. As the reaction proceeds, the sodium polyacrylate further reacts and generates subsequent thrust, thereby ensuring stable movement of the injection plug 203 toward the liquid storage area.

[0074] It is worth noting that the reaction area in this embodiment is inside the expansion chamber 213. Therefore, when injecting the reaction liquid into the reaction area through the liquid injection port 204, there is no need to pull out the rubber at the liquid injection port 204. The needle of the syringe can directly penetrate the rubber in the liquid injection port 204 and inject the reaction liquid into the reaction area.

[0075] Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and variations may be made to these embodiments without departing from the principles and spirit of the invention, and that the scope of the invention is limited by the accompanying embodiments and their equivalents.

Claims

1. A mouse-worn microinjection device for sustained release of salidroside, comprising a fixing frame (1), a slow injection device (2) disposed at the upper end of the fixing frame (1), and a flow guide (3) connected to the slow injection device (2), characterized in that: The slow injection device (2) comprises a syringe body (201) with a liquid storage area and a reaction area provided therein, an injection plug (203) being provided between the liquid storage area and the reaction area, and the side of the injection plug (203) being in contact with the inner wall of the syringe body (201), and the flow guide (3) being in communication with the liquid storage area; The upper end of the syringe body (201) is provided with a liquid injection port (204) connected to the reaction zone and a drug injection port (205) connected to the liquid storage zone, respectively, and the interiors of the liquid injection port (204) and the drug injection port (205) are filled with rubber. At the same time, one end of the syringe body (201) is connected to the deflector (3), and the other end is provided with a sealing cover (202). The interior of the reaction zone is provided with an active reaction component, and the sealing cover (202) is provided on the side of the active reaction component. At the same time, the injection plug (203) moves due to the change of the active reaction component and injects the drug inside the liquid storage zone to the outside.

2. The mouse-wearable microinjection device for sustained release of salidroside according to claim 1, characterized in that: The fixing frame (1) includes a mouthpiece (101), a head fixing piece (105), and a plurality of expansion pieces (108) connected in sequence; the strap piece (103) located at the end of the mouthpiece (101) and the head adapter opening (106) located on both sides of the head fixing piece (105) are fixedly connected via a head fixing strap (104); and the fixing ears (206) located on both sides of the syringe body (201) and the expansion piece (108) are fixedly connected via an auxiliary fixing strap (109); Mouth rings (102) are provided on both sides of the muzzle (101), the end of the deflector (3) passes through the mouth ring (102), and the ear hanging openings (107) located on the sides of the head adapter opening (106) fit the ears of the mouse.

3. The mouse-wearable microinjection device for sustained release of salidroside according to claim 1, characterized in that: The active reaction component includes but is not limited to a deformable medicine chamber (207), an expansion bag (210) and an expansion chamber (213), and the injection plug (203) moves due to changes in the medicine chamber (207), the expansion bag (210) and the expansion chamber (213), and at the same time, the volume of the reaction zone of the medicine chamber (207) / expansion bag (210) arranged therein is smaller than the volume of the reaction zone of the expansion chamber (213) arranged therein.

4. The mouse-wearable microinjection device for sustained release of salidroside according to claim 3, characterized in that: A pill (208) is provided inside the medicine chamber (207) opened in the middle of the sealing cover (202). The pill (208) is isolated from the reaction zone by an aluminum foil (209), and the pill (208) and the injection plug (203) are arranged opposite to each other. At the same time, the pill (208) falls into the interior of the reaction zone by pressing the medicine chamber (207) and squeezing the aluminum foil (209).

5. The mouse-wearable microinjection device for sustained release of salidroside according to claim 4, characterized in that: The pill (208) includes a medicine body (214), the outer surface of the medicine body (214) is provided with a wax sealing layer (215), and the wax sealing layer (215) is provided with a notch, and the medicine body (214) is in contact with the interior of the reaction zone through the notch.

6. The mouse-wearable microinjection device for sustained release of salidroside according to claim 3, characterized in that: The expansion bag (210) arranged on the side of the injection plug (203) facing the reaction zone includes an expansion cavity (219), a plurality of expansion drug layers (221) and a plastic sealing tape (218), wherein the expansion cavity (219) and the plurality of expansion drug layers (221) are arranged inside the plastic sealing tape (218), and the expansion cavity (219) and the expansion drug layers (221) and two adjacent expansion drug layers (221) are spaced apart by cotton sheets (220); A plurality of through holes (222) are provided at one end of the plastic sealing tape (218) close to the expansion drug layer (221), and the expansion drug layer (221) is connected to the interior of the reaction zone through the through holes (222).

7. A mouse-wearable microinjection device for sustained release of salidroside according to claim 4 or 6, characterized in that: The injection plug (203) includes two pistons connected by a connecting rod (216), and an arc groove (217) is provided on the outward side of the piston facing the liquid storage area. At the same time, the middle of the arc groove (217) is in contact with the end of the deflector (3), and the side of the piston facing the reaction area is in close contact with and perpendicular to the inner wall of the syringe body (201).

8. The mouse-wearable microinjection device for sustained release of salidroside according to claim 3, characterized in that: The interior of the expansion chamber (213) provided on one side of the injection plug (203) is filled with a solid expansion material and a guide strip (212). The expansion chamber (213) and the reaction zone are spaced apart by a spacer (211), and the end of the guide strip (212) passes through the spacer (211) and is connected to the interior of the reaction zone.

9. The mouse-wearable microinjection device for sustained release of salidroside according to claim 8, characterized in that: The guide strip (212) disposed inside the expansion chamber (213) is provided with redundancy, and the end of the guide strip (212) is connected to the side of the injection plug (203) in a wave-like manner.

10. A mouse-wearable microinjection device for sustained release of salidroside according to claim 8 or 9, characterized in that: The injection plug (203) comprises two pistons connected by a connecting rod (216), and the side surfaces of the pistons are in close contact with and perpendicular to the inner wall of the syringe body (201).

Images